Current Status of Newer Carbapenems

Author(s): Matteo Bassetti, Laura Nicolini, Silvano Esposito, Elda Righi, Claudio Viscoli.

Journal Name: Current Medicinal Chemistry

Volume 16 , Issue 5 , 2009

Become EABM
Become Reviewer

Abstract:

Objectives: Beta-lactam antibiotics represent the most commonly prescribed antibacterial agents. Since many bacteria have developed resistance to older agents, new beta-lactams have been introduced constantly. In the late 1970s, a new class of exceptionally broad-spectrum beta-lactams, the carbapenems, was identified. The carbapenems, such as the most popular imipenem and meropenem, have the widest spectra of antibacterial activity of all the beta-lactams and provide excellent coverage of many gram-negative and gram-positive aerobic and anaerobic bacteria. Despite the wide antibacterial spectrum, the carbapenems globally lack activity against Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA) and Stenotrophomonas maltophilia. Methods: We reviewed the principal characteristics of the novel carbapenems and their clinical implications. Results and conclusions: We included in our review: ertapenem, biapenem, panipenem, doripenem, tebipenem pivoxil and tomopenem.

Keywords: Carbapenems, imipenem, meropenem, ertapenem, biapenem, panipenem, tebipenem pivoxil, doripenem

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 5
Year: 2009
Page: [564 - 575]
Pages: 12
DOI: 10.2174/092986709787458498
Price: $58

Article Metrics

PDF: 15